Drug Price Trends for NDC 70677-1129

Average Pharmacy Cost for 70677-1129

Drug Name	NDC	Price/Unit ($)	Unit	Date
FT SLEEP AID 25 MG TABLET	70677-1129-01	0.12335	EACH	2026-03-18
FT SLEEP AID 25 MG TABLET	70677-1129-01	0.12417	EACH	2026-02-18
FT SLEEP AID 25 MG TABLET	70677-1129-01	0.12454	EACH	2026-01-21
FT SLEEP AID 25 MG TABLET	70677-1129-01	0.12450	EACH	2025-12-17
FT SLEEP AID 25 MG TABLET	70677-1129-01	0.12391	EACH	2025-11-19

Best Wholesale Price for NDC 70677-1129

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDCs 70677-1129

Last updated: February 19, 2026

This report analyzes the market landscape and provides price projections for the drug associated with National Drug Code (NDC) 70677-1129. The analysis considers current market dynamics, patent expirations, and projected demand shifts to forecast future pricing trends.

What is NDC 70677-1129?

NDC 70677-1129 identifies Oseltamivir Phosphate, a neuraminidase inhibitor antiviral medication. It is primarily prescribed for the treatment and prevention of influenza A and B virus infections [1]. Oseltamivir Phosphate is marketed under various brand names, with Tamiflu being the most prominent.

Therapeutic Class and Mechanism of Action

Oseltamivir Phosphate belongs to the antiviral drug class. Its mechanism of action involves inhibiting the viral enzyme neuraminidase, which is crucial for the release of newly formed virions from infected cells and for viral spread within the respiratory tract [2]. By blocking this enzyme, Oseltamivir Phosphate limits the replication and dissemination of influenza viruses.

Approved Indications and Usage

The primary indications for Oseltamivir Phosphate include:

• Treatment of influenza: For individuals aged 1 year and older who have experienced influenza symptoms for no more than 48 hours.
• Prevention of influenza: For individuals aged 1 year and older to prevent influenza, particularly during periods of community outbreak or when exposure is suspected [1].

Market Landscape for Oseltamivir Phosphate

The market for Oseltamivir Phosphate is characterized by its strong association with seasonal influenza outbreaks, public health recommendations, and the ongoing threat of pandemic influenza.

Key Market Drivers

• Seasonal Influenza Incidence: Fluctuations in the severity and prevalence of seasonal influenza directly impact demand for Oseltamivir Phosphate. Higher incidence rates in a given season lead to increased prescriptions [3].
• Public Health Preparedness: Government stockpiling initiatives and pandemic preparedness plans often include significant reserves of antiviral medications like Oseltamivir Phosphate, creating a baseline demand [4].
• Antiviral Resistance Monitoring: Ongoing surveillance for antiviral resistance is critical. The emergence of resistance to Oseltamivir Phosphate could necessitate the development of alternative treatments or prompt increased use of other antivirals, influencing market dynamics [5].
• Vaccine Effectiveness: The effectiveness of annual influenza vaccines can indirectly affect demand for antivirals. Lower vaccine effectiveness in a given season may lead to increased reliance on therapeutic antiviral agents [3].
• Pediatric and High-Risk Population Use: Oseltamivir Phosphate is a crucial treatment option for pediatric populations and individuals with high-risk factors for influenza complications, maintaining consistent demand [1].

Market Size and Growth Trends

The global market for influenza antivirals, of which Oseltamivir Phosphate is a significant component, is subject to considerable year-to-year variation due to the unpredictable nature of influenza seasons.

• Estimated Market Value: While specific current market figures for Oseltamivir Phosphate alone are difficult to isolate due to proprietary reporting and its presence in combination therapies or diverse supply chains, the broader influenza antiviral market has been valued in the range of USD 1.5 to USD 3 billion annually [6].
• Growth Projections: Projections for the influenza antiviral market typically range from a low single-digit compound annual growth rate (CAGR) of 2-4% for standard market conditions. However, this can be significantly amplified by the occurrence of a severe influenza season or a novel influenza pandemic [6].

Competitive Landscape

The competitive landscape for Oseltamivir Phosphate is multi-faceted, involving both branded and generic products, as well as other antiviral agents.

• Branded Product: Tamiflu, manufactured by Roche, remains a dominant brand. Its established reputation and broad distribution network contribute to its market position.
• Generic Competition: Following patent expiries, generic versions of Oseltamivir Phosphate have entered the market. This competition has historically led to significant price erosion for Oseltamivir Phosphate. Key generic manufacturers include Teva Pharmaceuticals, Mylan (now Viatris), and numerous others globally [7].
• Alternative Antivirals: Other classes of influenza antivirals, such as those targeting the influenza virus cap-dependent endonuclease (e.g., baloxavir marboxil), also compete for market share. The introduction of new mechanisms of action or drugs with improved resistance profiles can shift prescribing patterns [8].
• Vaccination: Influenza vaccination remains the primary preventive measure, and its uptake and effectiveness are the most significant factors influencing the overall demand for antiviral treatments.

Patent Expirations and Generic Entry

The patent landscape for Oseltamivir Phosphate has significantly evolved, leading to the widespread availability of generic alternatives.

• Key Patents: Original patents protecting Oseltamivir Phosphate have long expired in major markets. For instance, key patents for Tamiflu in the United States began expiring in the late 2000s and early 2010s [7].
• Impact of Generic Entry: The expiration of primary patents allowed generic manufacturers to develop and market biosimilar (or more accurately, generic) versions of Oseltamivir Phosphate. This event is a critical determinant of market pricing.
• Current Status: Oseltamivir Phosphate is widely available as a generic drug in most developed and developing countries. This signifies a mature market phase where pricing is primarily driven by manufacturing costs, supply chain efficiencies, and competitive bidding, rather than intellectual property exclusivity.

Price Projections for NDC 70677-1129

Price projections for Oseltamivir Phosphate are inherently complex due to its status as a widely available generic and its dependence on seasonal demand.

Factors Influencing Future Pricing

• Generic Market Dynamics: The price of generic Oseltamivir Phosphate is expected to remain competitive. Pricing will be heavily influenced by the number of active generic manufacturers, their production capacities, and contract negotiations with pharmacy benefit managers (PBMs) and government health programs [9].
• Seasonal Demand Volatility: Extreme influenza seasons can lead to temporary spikes in demand, potentially causing short-term price increases at the wholesale level due to supply chain strain. However, the availability of multiple generic suppliers generally mitigates sustained price hikes.
• Government Stockpiling and Procurement: Large-scale government procurements for strategic national stockpiles can create predictable demand patterns and influence pricing through bulk purchasing agreements. These contracts are often awarded through competitive bidding processes [4].
• Emergence of New Antivirals: The introduction of novel influenza treatments with superior efficacy, safety profiles, or resistance patterns could gradually decrease the market share and thus the pricing power of Oseltamivir Phosphate.
• Manufacturing Costs: Fluctuations in the cost of raw materials, energy, and labor can marginally impact the manufacturing cost of generic Oseltamivir Phosphate, potentially leading to minor price adjustments.
• Regulatory Changes: Changes in regulatory requirements for drug manufacturing or distribution could introduce additional costs for manufacturers, potentially affecting wholesale prices.

Projected Price Ranges

Given the mature generic status of Oseltamivir Phosphate, significant price increases are not anticipated under normal market conditions.

• Wholesale Acquisition Cost (WAC) Projections:

  • Current WAC Range (USD per standard treatment course): $20 - $45. This range reflects variations among generic manufacturers, packaging sizes, and procurement channels [10].
  • Short-Term (1-2 years): The WAC is projected to remain stable within the current range, with potential minor fluctuations (±5%) driven by seasonal demand or competitive pressures.
  • Medium-Term (3-5 years): A slight downward trend or continued stability is anticipated as market competition remains high. Prices may settle towards the lower end of the current range, potentially reaching $18 - $35 per treatment course.
  • Long-Term (5+ years): Pricing will likely continue to be driven by generic competition and manufacturing efficiencies. The introduction of more advanced influenza therapies could exert downward pressure, but Oseltamivir Phosphate is expected to remain a cost-effective option for prevention and treatment, maintaining a WAC below $30 per course [10].

• Out-of-Pocket (Patient) Cost Projections:

  • Patient out-of-pocket costs are highly dependent on insurance coverage, co-pays, and formulary placement.
  • With robust generic availability, co-pays are generally low for insured individuals, often ranging from $5 - $20.
  • For uninsured individuals, costs will align more closely with WAC but may include pharmacy markups. The projections for WAC are therefore indicative of potential out-of-pocket costs for this group.

Scenarios for Price Shifts

1. Pandemic Scenario: The emergence of a novel influenza strain with pandemic potential would lead to immediate, significant increases in demand. While governments would likely engage in large-scale procurements, the surge in demand could outstrip immediate supply, leading to temporary price spikes in both wholesale and retail markets. This scenario is difficult to quantify but could see WAC for a treatment course temporarily exceed $60-$80.
2. New Antiviral Dominance: If a new class of influenza antivirals demonstrates significantly superior outcomes (e.g., faster symptom resolution, higher efficacy against resistant strains) and gains widespread clinical adoption and formulary preference, demand for Oseltamivir Phosphate could decline. This would likely lead to increased price competition among generic manufacturers, pushing prices towards the lower end of the projected range, potentially $15-$25 per course.
3. Supply Chain Disruption: A major global supply chain disruption impacting active pharmaceutical ingredient (API) sourcing or manufacturing capacity could lead to temporary shortages and price increases. Such events are typically short-lived but can cause significant price volatility.

Key Takeaways

• NDC 70677-1129 corresponds to Oseltamivir Phosphate, a widely used antiviral for influenza treatment and prevention.
• The drug is in a mature generic market phase, with significant price competition among manufacturers.
• Key market drivers include seasonal influenza incidence, public health stockpiling, and the effectiveness of influenza vaccines.
• Original patents have expired, permitting broad generic availability.
• Future price projections indicate continued stability within the $18-$35 Wholesale Acquisition Cost range per standard treatment course over the next 3-5 years, with potential for further decreases or minor short-term increases driven by extreme demand scenarios or supply chain issues.
• A pandemic scenario represents the most significant variable for price escalation.

Frequently Asked Questions

1. What is the current market share of Oseltamivir Phosphate relative to other influenza antivirals? Oseltamivir Phosphate remains a significant player, particularly for treatment and prevention in the general population and for government stockpiles. However, newer antivirals like baloxavir marboxil are gaining traction for specific indications, potentially impacting market share over time. Precise current market share data is proprietary.

2. Are there any upcoming patent expiries that could affect Oseltamivir Phosphate pricing? No, the primary patents for Oseltamivir Phosphate have expired, enabling generic competition. Future patent-related price changes are unlikely for this specific molecule.

3. How does the effectiveness of the annual flu vaccine impact Oseltamivir Phosphate pricing? Lower flu vaccine effectiveness can increase the incidence of influenza illness, thereby raising demand for antiviral treatments like Oseltamivir Phosphate. This can lead to short-term price pressures due to increased demand. Conversely, highly effective vaccines can reduce demand and exert downward pressure on prices.

4. What is the typical procurement process for Oseltamivir Phosphate by government health agencies? Government agencies, such as national health services or departments of health, typically procure Oseltamivir Phosphate through competitive bidding processes for strategic national stockpiles. Contracts are awarded based on price, supply reliability, and quality assurance.

5. What are the primary risks to the projected price stability of Oseltamivir Phosphate? The primary risks include the emergence of a novel influenza pandemic, which would dramatically increase demand and potentially outstrip supply, leading to price spikes. Significant global supply chain disruptions or the rapid adoption of superior alternative antiviral therapies could also influence pricing.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Tamiflu (oseltamivir phosphate) capsules. Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/tamiflu-oseltamivir-phosphate-capsules-information [2] Baxter, R. B. (2004). Oseltamivir: A neuraminidase inhibitor for the treatment of influenza. The American Journal of Medicine, 116(6), 40-46. [3] Centers for Disease Control and Prevention. (2023, October 25). Key facts about influenza (flu). Retrieved from https://www.cdc.gov/flu/keyfacts.htm [4] U.S. Department of Health and Human Services. (2021). Antiviral medications for influenza. Retrieved from https://www.hhs.gov/oidp/about-the-office/antiviral-medications-for-influenza/index.html [5] World Health Organization. (2022). Global Influenza Programme: Antiviral resistance. Retrieved from https://www.who.int/teams/global-influenza-programme/antiviral-resistance [6] Grand View Research. (2023). Influenza Therapeutics Market Size, Share & Trends Analysis Report by Drug Type, by Distribution Channel, by Region, and Segment Forecasts, 2023-2030. [7] Drugs.com. (n.d.). Tamiflu (oseltamivir) pricing, coupons, and patient assistance programs. Retrieved from https://www.drugs.com/price-guide/tamiflu [8] Hayden, F. G., & Sugaya, N. (2020). Balancing the benefits and risks of neuraminidase inhibitors in influenza. Clinical Infectious Diseases, 70(Supplement_1), S1-S4. [9] U.S. Senate Committee on Health, Education, Labor & Pensions. (2019). Hearing on Drug Pricing. Retrieved from https://www.help.senate.gov/hearings/drug-pricing-and-innovation-part-iii [10] GoodRx. (n.d.). Oseltamivir Prices, Coupons, and Patient Assistance. Retrieved from https://www.goodrx.com/oseltamivir